UCB (OTCMKTS:UCBJY) Sees Unusually-High Trading Volume – Still a Buy?

UCB SA (OTCMKTS:UCBJY) saw unusually-high trading volume on Friday . Approximately 76,781 shares traded hands during mid-day trading, an increase of 103% from the previous session’s volume of 37,756 shares.The stock last traded at $129.1150 and had previously closed at $129.33.

Analyst Ratings Changes

A number of research firms have issued reports on UCBJY. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

UCB Stock Down 0.2%

The firm has a 50-day moving average price of $142.52 and a 200-day moving average price of $146.82. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.